BGES Bio Bridge Science Inc (CE)

Bio-Bridge Science, Inc. (OTCBB: BGES) announced today that it has recorded the initial sales of Xinhua's surgical instruments. Late last year, Bio-Bridge Science entered into an exclusive agency agreement with Xinhua Surgical Instruments Co., Ltd., a leading global manufacturer of hundreds of instruments that meet the criteria for Class I medical devices by the FDA, under which Xinhua granted the Company exclusive distribution rights for all of Xinhua's surgical instruments sold in the U.S. The initial sales were for surgical scissors and forcepts. Recently, Bio-Bridge received notice confirming that it had successfully registered the products with the FDA and established a sales inventory of Xinhua's surgical instruments. The Company plans to use well-established distributors in addition to their own sales force to reach the potential market directly. The Company plans to offer high-quality instruments at reduced prices, which will provide for an opportunity to take market share quickly. "We are pleased to have recorded the first sales from Xinhua's extensive portfolio of products," said CEO Dr. Liang Qiao. "The potential market for their instruments is enormous, as doctors, veterinarians, researchers, and dentists throughout the United States can benefit from their leading-edge products. While the surgical instrument market in the U.S. is highly competitive, our plan to offer high-quality instruments at reduced prices will allow us to take market share quickly. We look forward to working with Xinhua as it receives FDA clearance." About Xinhua Surgical Instrument Company: Xinhua Surgical Instrument Co., Ltd, was established jointly by Aesculap International Co. Ltd, Germany and Shandong Shinva Medical Instruments Factory, China in 1997. Xinhua has established a first level production line which produces annually more than 2 million instruments. Using the surgical instrument processing techniques imported from Germany, Xinhua's products have big advantages based upon superior durability and performance. Some of the products include standard surgical instruments, neuro surgery instruments, micro surgery instruments, cervical and lumbar vertebra surgery instruments, thoracic and abdominal surgery instruments, urological surgery instruments, gynecologic and obstetric surgery instruments, special surgical instruments, dental instruments, non-chrome plated micro neuro surgery instruments, and head resting systems and electro-surgical motors. About Bio-Bridge Science: Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine, that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy" acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine to market as early as 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP research and manufacturing facility in Beijing, which is expected to be completed by mid-year.